<DOC>
	<DOC>NCT02961764</DOC>
	<brief_summary>This study will evaluate a new critical pathway (use of guideline-based patient identification criteria and for those who meet these criteria, use of dalbavancin) for the treatment of ABSSSI compared to usual care.</brief_summary>
	<brief_title>Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Dalbavancin</mesh_term>
	<criteria>Presents to the Emergency Department (ED) and meets the clinical definition for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Known or suspected grampositive infection. Known or suspected gramnegative infections, anaerobic infections, or fungemia Known or suspected infections that are severe, life threatening or are not included in the ABSSSI Food and Drug Administration (FDA) guidance Injection drug users with a fever Severe neurological disorder leading to immobility or confined to a wheelchair Bilateral Lower extremity involvement of the suspected infection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Critical Pathways</keyword>
	<keyword>Health Facilities</keyword>
	<keyword>Clinical Protocols</keyword>
	<keyword>Patient Satisfaction</keyword>
	<keyword>Absenteeism</keyword>
	<keyword>Anti-Bacterial Agents</keyword>
	<keyword>Quality of Life</keyword>
	<keyword>Economics, Medical</keyword>
	<keyword>Health Resources</keyword>
	<keyword>Health resource utilization</keyword>
	<keyword>Acute bacterial skin and skin structure infection (ABSSSI)</keyword>
</DOC>